Decheng Capital’s Krystal Biotech KRYS Stock Holding History

Decheng Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.89M	Sell	7,300 -10,000	-58%	-$2.66M	0.29%	13
2025 Q4	$4.27M	Sell	17,300 -15,000	-46%	-$3.16M	0.57%	13
2025 Q3	$5.7M	Sell	32,300 -33,700	-51%	-$5.04M	0.99%	14
2025 Q2	$9.07M	Buy	66,000 +1,000	+2%	+$147K	2.29%	8
2025 Q1	$11.7M	Sell	65,000 -11,772	-15%	-$1.98M	3.29%	6
2024 Q4	$12M	Buy	76,772 +5,000	+7%	+$887K	2.58%	7
2024 Q3	$13.1M	Buy	71,772 +6,000	+9%	+$1.16M	3.09%	5
2024 Q2	$12.1M	Hold	65,772	–	–	3.7%	5
2024 Q1	$11.7M	Hold	65,772	–	–	1.57%	7
2023 Q4	$8.16M	Buy	+65,772	New	+$7.29M	2.28%	12

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Decheng Capital's KRYS Position: Q1 2026 in Review

Decheng Capital reduced its Krystal Biotech (KRYS) stake by 58% in Q1 2026, selling an estimated $2.66M and leaving 7,300 shares worth $1.89M. The position accounts for 0.29% of the portfolio, ranked #13.

Decheng Capital first reported a position in KRYS in Q4 2023 and has held it in 10 quarters since. The position peaked at $13.1M in Q3 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Decheng Capital held 7,300 shares of Krystal Biotech worth $1.89M as of Q1 2026.
Decheng Capital sold 10,000 Krystal Biotech shares in Q1 2026, an estimated $2.66M.
Krystal Biotech made up 0.29% of Decheng Capital's portfolio in Q1 2026, its #13 holding.
Decheng Capital first reported a position in Krystal Biotech in Q4 2023 and has held it in 10 quarters since.
Decheng Capital's Krystal Biotech position peaked at $13.1M in Q3 2024.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.